12.2
Режимы дозирования: частичные фармакокинетические параметры
Нередко в фармакокинетике не удаётся получить полные фармакокинетические профили препарата. Это требует от фармакокинетиков принятия определённых обос…
Полные фармакокинетические профили многих лекарственных препаратов часто неизвестны или недоступны.
Таким образом, исследователям необходимо сделать несколько предположений для расчета режимов дозирования без фармакокинетических данных, в зависимости от безопасности, эффективности и терапевтического диапазона препарата.
Одним из распространенных предположений является установка коэффициента биодоступности, F, равным 1 или 100%.
Это гарантирует, что если лекарство не полностью всасывается, пациенты получают недостаточное лечение, а не чрезмерное количество лекарств.
Популяционная фармакокинетика использует средние характеристики популяции пациентов с ограниченными образцами концентраций препарата в сыворотке крови пациентов.
Использование популяционной фармакокинетики в терапевтическом лекарственном мониторинге возросло в связи с наличием компьютеризированных баз данных и развитием статистического инструментария для анализа данных наблюдений.
View the full transcript and gain access to JoVE Core videos
Q1: Why do researchers set the bioavailability factor to 1 when complete pharmacokinetic data is unavailable?
Setting the bioavailability factor, F, to 1 or 100% ensures that if a drug is not fully absorbed, patients are undermedicated rather than overmedicated. This conservative assumption prioritizes patient safety by erring on the side of caution when complete pharmacokinetic profiles remain unknown or unavailable.
Q2: What factors guide the selection of assumptions for dosage regimen calculations?
Pharmacokineticists select assumptions based on three key factors: the drug's safety profile, its efficacy, and its therapeutic range. These criteria ensure that educated assumptions about bioavailability and other parameters lead to appropriate dosage regimens that balance therapeutic effectiveness with patient protection.
Q3: How does population pharmacokinetics help when individual drug data is incomplete?
Population pharmacokinetics uses average patient population characteristics combined with limited serum drug concentration samples from patients to estimate dosing parameters. This approach has increased in therapeutic drug monitoring due to computerized databases and advanced statistical tools for analyzing observational data.
Q4: What role do computerized databases play in modern dosage regimen development?
Computerized databases enable population pharmacokinetics by storing and organizing large amounts of patient data and serum drug concentration information. Combined with statistical tools for observational data analysis, these databases facilitate the calculation of appropriate dosage regimens without requiring complete individual pharmacokinetic profiles.
Q5: Why is population pharmacokinetics increasingly used in therapeutic drug monitoring?
Population pharmacokinetics has gained prominence in therapeutic drug monitoring because it provides a practical alternative when complete pharmacokinetic profiles are unavailable. The availability of computerized databases and development of statistical tools for observational data analysis make this approach feasible and reliable for clinical practice.
Q6: What happens if a drug's bioavailability assumption is set too high?
If the bioavailability factor is set too high, patients may receive insufficient drug doses, resulting in undermedication and reduced therapeutic effectiveness. This is why researchers conservatively set F to 1 or 100% when complete absorption data is unknown, prioritizing patient safety over potential overmedication risks.
Q7: How do statistical tools support dosage regimen calculations in population pharmacokinetics?
Statistical tools designed for observational data analysis enable pharmacokineticists to extract meaningful pharmacokinetic information from limited serum drug concentration samples across patient populations. These tools help calculate reliable dosage regimens by identifying patterns and relationships in population-level data when individual complete profiles are unavailable.